Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib
| Class:Id | LiteratureReference:9702293 |
|---|
| _displayName | Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib |
|---|
| _timestamp | 2020-09-29 20:56:35 |
|---|
| author | [Person:9702298] Ignatius Ou, Sai-Hong
[Person:9702299] Azada, Michele
[Person:9702295] Hsiang, David J
[Person:9702297] Herman, June M
[Person:9702294] Kain, Tatiana S
[Person:9702300] Siwak-Tapp, Christina
[Person:9702301] Casey, Cameron
[Person:5662780] He, Jie
[Person:5655437] Ali, Siraj M
[Person:9634510] Klempner, Samuel J
[Person:6800578] Miller, Vincent A |
|---|
| created | [InstanceEdit:9702296] Rothfels, Karen, 2020-09-29 |
|---|
| journal | J Thorac Oncol |
|---|
| pages | 549-53 |
|---|
| pubMedIdentifier | 24736079 |
|---|
| title | Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib |
|---|
| volume | 9 |
|---|
| year | 2014 |
|---|
| (literatureReference) | [DefinedSet:9700564] crizotinib resistant ALK mutants [plasma membrane] [Homo sapiens]
[Reaction:9700662] Liganded-ALK dimer binds type I ALK-binding TKIs [Homo sapiens]
[FailedReaction:9715357] crizotinib-resistant ALK mutants don't bind crizotinib [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib (9702293)
